抗坏血酸对常用抗阿米巴药物二碘羟基喹啉致突变性的体内抗诱变作用。

In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline.

作者信息

Ghaskadbi S, Vaidya V G

机构信息

Department of Zoology, M.A.C.S. Research Institute, Pune, India.

出版信息

Mutat Res. 1989 Mar;222(3):219-22. doi: 10.1016/0165-1218(89)90137-7.

DOI:10.1016/0165-1218(89)90137-7

PMID:2493578

Abstract

We have previously shown that the common antiamebic drug diiodohydroxyquinoline (DIHQ) exhibits mutagenic activity in the in vivo micronucleus test in Swiss albino mice. Results of experiments undertaken to study the influence of ascorbic acid (vitamin C) on the mutagenicity of DIHQ in this model system showed that ascorbic acid acts as an antimutagen against DIHQ. The effective antimutagenic doses of ascorbic acid themselves do not show any genotoxic effects in this in vivo system. It will be necessary, however, to elucidate the mechanism of action of ascorbic acid as well as its effects on the therapeutic properties of DIHQ before a practical use of ascorbic acid is contemplated for this purpose.

摘要

我们之前已经表明，常见的抗阿米巴药物二碘羟基喹啉（DIHQ）在瑞士白化小鼠的体内微核试验中表现出诱变活性。在该模型系统中研究抗坏血酸（维生素C）对DIHQ诱变性影响的实验结果表明，抗坏血酸可作为针对DIHQ的抗诱变剂。抗坏血酸自身的有效抗诱变剂量在该体内系统中未显示出任何遗传毒性作用。然而，在考虑将抗坏血酸实际用于此目的之前，有必要阐明其作用机制以及对DIHQ治疗特性的影响。